Madrigal May Shake Up NASH Race With Phase II Resolution Data
Madrigal reports data showing that MGL-3196 resolved non-alcoholic steatohepatitis and improved key secondary measures, data that suggest a better effect than other NASH candidates.
You may also be interested in...
With resmetirom hitting its co-primary endpoints, Madrigal intends to file the THRβ agonist for approval during H1 2023 in the liver disease, an unmet medical need with blockbuster earnings potential.
Madrigal’s selective THR beta agonist continues to demonstrate hepatic fat-lowering abilities in 36-week data, along with lipid-lowering characteristics. The company hopes to initiate a Phase III study in early 2019.
In a Phase II study, Viking’s VK2809, with the same mechanism as Madrigal’s MGL-3196, shows significant liver fat reduction in NAFLD patients, along with reduction in LDL cholesterol.